DOCSLIB.ORG

E000764.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
E000764.Full.Pdf Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-000764 on 26 November 2020. Downloaded from Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4 Lisa A Marshall,1 Sachie Marubayashi,2 Aparna Jorapur,1 Scott Jacobson,1 Mikhail Zibinsky,1 Omar Robles,1 Dennis Xiaozhou Hu,3 Jeffrey J Jackson,1 Deepa Pookot,1 Jerick Sanchez,1 Martin Brovarney,1 Angela Wadsworth,1 David Chian,4 David Wustrow,1 Paul D Kassner,1 Gene Cutler,1 Brian Wong,1 1 1 Dirk G Brockstedt, Oezcan Talay To cite: Marshall LA, ABSTRACT Statement of significance CPI upregulates CCL17 and Marubayashi S, Jorapur A, et al. Background Checkpoint inhibitors (CPIs) such as anti- CCL22 expression in tumors and increases Treg migration Tumors establish resistance to PD(L)-1 and anti- CTLA-4 antibodies have resulted in into the TME. Pharmacological antagonism of the CCR4 immunotherapy by regulating unprecedented rates of antitumor responses and extension receptor effectively inhibits T recruitment and results T recruitment via CCR4. reg reg of survival of patients with a variety of cancers. But in enhanced antitumor efficacy either as single agent in Journal for ImmunoTherapy some patients fail to respond or initially respond but later CCR4 ligandhigh tumors or in combination with CPIs in of Cancer 2020;8:e000764. low doi:10.1136/jitc-2020-000764 relapse as they develop resistance to immune therapy. CCR4 ligand tumors. One of the tumor- extrinsic mechanisms for resistance to immune therapy is the accumulation of regulatory T cells ► Additional material is published online only. To view (Treg) in tumors. In preclinical and clinical studies, it has INTRODUCTION been suggested that tumor trafficking of T is mediated please visit the journal online reg In recent years, it has become clear that (http:// dx. doi. org/ 10. 1136/ jitc- by CC chemokine receptor 4 (CCR4). Over 90% of human tumors use various immunomodulatory 2020- 000764). T express CCR4 and migrate toward CCL17 and CCL22, reg pathways and recruit suppressive cells as a two major CCR4 ligands that are either high at baseline LAM and SM contributed or upregulated in tumors on CPI treatment. Hence, CCR4 major mechanism of immune resistance, equally. antagonism has the potential to be an effective antitumor particularly against tumor- specific effector T cells (T ).1 2 Cancer immunotherapy with treatment by reducing the accumulation of Treg into the eff Accepted 25 August 2020 tumor microenvironment (TME). monoclonal antibodies that effectively block Methods We developed in vitro and in vivo models PD(L)-1 and CTLA-4 are designed to enhance to assess Treg migration and antitumor efficacy using a antitumor immunity and have shown promise http://jitc.bmj.com/ potent and selective CCR4 antagonist, CCR4-351. We in the treatment of patients with solid tumors used two separate tumor models, Pan02 and CT26 mouse and hematologic malignancies.3–7 However, tumors, that have high and low CCR4 ligand expression, only a subset of patients responds to these respectively. Tumor growth inhibition as well as the checkpoint inhibitor treatments with durable frequency of tumor- infiltrating T and effector T cells was reg clinical benefit, and most patients with cancer assessed following the treatment with CCR4 antagonist fail to respond to the treatment at all or on September 29, 2021 by guest. Protected copyright. alone or in combination with CPI. 3 5 Results Using a selective and highly potent, novel small relapse. The tumor- extrinsic mechanisms of molecule inhibitor of CCR4, we demonstrate that migration either the primary or the acquired resistance © Author(s) (or their + are not fully understood, but evidence points of CCR4 Treg into the tumor drives tumor progression and employer(s)) 2020. Re- use to the accumulation of suppressor cells, such permitted under CC BY-NC. No resistance to CPI treatment. In tumor models with high commercial re- use. See rights baseline levels of CCR4 ligands, blockade of CCR4 reduced as regulatory T cells (Treg), in the tumor as 8 and permissions. Published by the number of Treg and enhanced antitumor immune one such mechanism. BMJ. activity. Notably, in tumor models with low baseline level + + Naturally suppressive CD4 Foxp3 Treg are 1RAPT Therapeutics, South San of CCR4 ligands, treatment with immune CPIs resulted in essential for immune tolerance. Although Francisco, California, USA significant increases of CCR4 ligands and regT numbers. 2 Treg- mediated suppression of effector cells is Arcus Biosciences Inc, Inhibition of CCR4 reduced T frequency and potentiated 9 reg important to maintain host self-tolerance, Hayward, California, USA the antitumor effects of CPIs. 3 the presence of T in the tumor microenvi- Genentech Inc, South San Conclusion Taken together, we demonstrate that CCR4- reg Francisco, California, USA dependent T recruitment into the tumor is an important ronment (TME) has been shown to dampen 4Lyell Immunopharma, South reg 10 11 tumor- extrinsic mechanism for immune resistance. antitumor immune responses. In fact, San Francisco, California, USA studies revealed that elevated frequencies Blockade of CCR4 led to reduced frequency of Treg and Correspondence to resulted in increased antitumor activity, supporting the of Treg at the tumor site correlate with poor Dr Dirk G Brockstedt; clinical development of CCR4 inhibitors in combination clinical outcome, raising the need for a treat- dbrockstedt@ rapt. com with CPI for the treatment of cancer. ment to reduce the number of Treg in the Marshall LA, et al. J Immunother Cancer 2020;8:e000764. doi:10.1136/jitc-2020-000764 1 Open access J Immunother Cancer: first published as 10.1136/jitc-2020-000764 on 26 November 2020. Downloaded from 12–14 tumor. The observed increased frequency of Treg cells of Medicine, Stanford University). Pan02- OVA cells were has been hypothesized to be attributed to the expansion engineered by stable transduction of Pan02 cells with of tumor- resident Treg, conversion from conventional pChac- puro plasmid expressing full-length chicken oval- + CD4 T cells, or migration of Treg from the periphery bumin (OVA; LakePharma). All cells were confirmed into the TME. Evidence indicates that Treg are actively mycoplasma negative and identity of all cell lines was vali- recruited to the TME by surface receptors that recognize dated by short- tandem repeat profiling. chemokines that are highly expressed within the TME.15 The CC chemokine receptor 4 (CCR4) is expressed on CCR4 antagonist 16 most (>90%) human Treg. In patients with various types The discovery of the selective and potent small molecule of cancers, such as ovarian, lung and breast cancer, high CCR4 inhibitor (referenced as CCR4-351 in this manu- levels of CCR4 ligands (CCL17 and CCL22) are produced script) is described elsewhere.22 This novel compound by tumor cells, tumor- associated macrophages17 and/or was designed, synthesized and characterized at RAPT dendritic cells (DCs).18 Importantly, recent preclinical Therapeutics. In several experiments, an independent and clinical studies demonstrated that the number of CCR4 antagonist highly related to CCR4-351 was used. intratumoral Treg increased in subjects after treatment The potency, selectivity and pharmacokinetic properties with immunotherapies.19 20 However, whether immuno- of this antagonist are similar to CCR4-351. therapies increase levels of CCR4 ligands in the tumor and result in the increased migration of Treg is not well Antibodies and reagents understood. Antibodies and dyes used for surface staining: unless In this study, we demonstrated that immune resistance specified, antibodies were purchased from BioLegend, in several mouse tumor models, at least in part, is estab- San Diego. Anti- CD45 BV510 (clone 30-F11), anti- CD4 lished by producing high levels of the two CCR4 ligands, APC- Cy7 (clone RM4-5), anti-CD8 FITC (clone 53-6.7), CCL17 and CCL22, leading to the recruitment of CCR4+ anti- CD69 PE (clone H1.2F3), anti- PD-1 PE- Cy7 (clone Treg into the TME. This finding is supported by gene 29F.1A12, BD Biosciences), anti-CCR4 APC (clone 2G12), expression data from various human tumors, suggesting anti- CCR4 PerCP/CY5.5 (clone L291H4), anti- CCR5 that high CCL17 and CCL22 gene expression strongly PE (clone HEK/1/85), anti- CCR6 PE (clone G034E3), correlates with increased Treg presence as assessed by anti- CCR7 PE (clone G034H7), anti- CXCR3 PE (clone FOXP3 expression.21 In contrast, there was poor correla- G025H7), anti- CD45RA BV510 (clone HI100), anti- tion between FOXP3 and other chemokine ligands or CD45RO Pacific Blue (clone UCHL1), anti-CD25 APC- transforming growth factor beta (TGF-β) expression, CY7 (clone BC96), anti-CD127 APC (clone A019D5), suggesting that Treg accumulation occurs predominantly anti- CD4 FITC (clone GK1.5) and 7AAD. Reagents and through CCR4- mediated recruitment. A selective and antibodies used for intracellular staining: cells were fixed potent small molecule CCR4 inhibitor (CCR4-351) and permeabilized following the protocol for the FoxP3/ effectively blocked migration of Treg into the tumor and Transcription Factor Staining Buffer (eBiosciences). increased single-agent antitumor efficacy in CCR4 ligand- Fixable viability dye eFluor780 (eBiosciences) and anti- http://jitc.bmj.com/ high mouse tumors. Interestingly, treatment with check- FoxP3 APC (clone FJK- 16s, eBiosciences). Sample acqui- point inhibitors such as anti- CTLA-4 antibody or other sition was performed on either a FACSCanto II or
Load more

Recommended publications
  • T Cell Binding to Activated Dendritic Cells Cutting Edge
    Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang and Sam T. Hwang This information is current as J Immunol 2001; 167:4791-4795; ; of September 27, 2021. doi: 10.4049/jimmunol.167.9.4791 http://www.jimmunol.org/content/167/9/4791 Supplementary http://www.jimmunol.org/content/suppl/2001/10/11/167.9.4791.DC1 Downloaded from Material References This article cites 32 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/9/4791.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. ● Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang, and Sam T. Hwang1 DC. In the periphery, activated, Ag-bearing DC may bind to cog- The binding of a T cell to an Ag-laden dendritic cell (DC) is a nate effector memory T cells (mTC).
    [Show full text]
  • Mechanism of Macrophage-Derived Chemokine/CCL22 Production by Hacat Keratinocytes
    C Yano, et al Ann Dermatol Vol. 27, No. 2, 2015 http://dx.doi.org/10.5021/ad.2015.27.2.152 ORIGINAL ARTICLE Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes Chizuko Yano, Hidehisa Saeki1, Mayumi Komine2, Shinji Kagami3, Yuichiro Tsunemi4, Mamitaro Ohtsuki2, Hidemi Nakagawa Department of Dermatology, The Jikei University School of Medicine, 1Department of Dermatology, Nippon Medical School, Tokyo, 2Department of Dermatology, Jichi Medical University, Shimotsuke, 3Department of Dermatology, Kanto Central Hospital, 4Department of Dermatology, Tokyo Women’s Medical University, Tokyo, Japan Background: CC chemokine ligand 17 (CCL17) and CCL22 27(2) 152∼156, 2015) are the functional ligands for CCR4. We previously reported that inhibitors of nuclear factor-kappa B and p38 mi- -Keywords- togen-activated protein kinase (p38 MAPK), but not of ex- Chemokine CCL22, Chemokine CCL17, Epidermal growth tracellular signal-related kinase (ERK), inhibited tumor ne- factor receptor, HaCaT keratinocytes crosis factor (TNF)-α- and interferon (IFN)-γ-induced pro- duction of CCL17 by the human keratinocyte cell line, HaCaT. Further, an inhibitor of epidermal growth factor re- INTRODUCTION ceptor (EGFR) enhanced the CCL17 production by these keratinocytes. Objective: To identify the mechanism under- The macrophage-derived chemokine (MDC)/CC chemo- lying CCL22 production by HaCaT cells. Methods: We inves- kine ligand 22 (CCL22) is one of the functional ligands for tigated the signal transduction pathways by which TNF-α CC chemokine receptor 4 (CCR4) and is a chemoattractant and IFN-γ stimulate HaCaT cells to produce CCL22 by add- for the CCR4-expressing cells such as Th2 cells. We and ing various inhibitors.
    [Show full text]
  • Differential Expression of Interferon-Γ and Chemokine Genes
    Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Owens et al. Owens et al. Journal of Neuroinflammation 2013, 10:56 http://www.jneuroinflammation.com/content/10/1/56 Owens et al. Journal of Neuroinflammation 2013, 10:56 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/56 NEUROINFLAMMATION RESEARCH Open Access Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Geoffrey C Owens1,7*, My N Huynh1, Julia W Chang1, David L McArthur1, Michelle J Hickey2, Harry V Vinters2,3, Gary W Mathern1,4,5,6† and Carol A Kruse1,6† Abstract Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy. Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
    [Show full text]
  • HIV-1 Tat Protein Mimicry of Chemokines
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 13153–13158, October 1998 Immunology HIV-1 Tat protein mimicry of chemokines ADRIANA ALBINI*, SILVANO FERRINI*, ROBERTO BENELLI*, SABRINA SFORZINI*, DANIELA GIUNCIUGLIO*, MARIA GRAZIA ALUIGI*, AMANDA E. I. PROUDFOOT†,SAMI ALOUANI†,TIMOTHY N. C. WELLS†, GIULIANO MARIANI‡,RONALD L. RABIN§,JOSHUA M. FARBER§, AND DOUGLAS M. NOONAN*¶ *Centro di Biotecnologie Avanzate, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132 Genoa, Italy; †Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, 14 chemin des Aulx, 1228 Plan-les Ouates, Geneva, Switzerland; ‡Dipartimento di Medicina Interna, Medicina Nucleare, University of Genova, Viale Benedetto XV, 6, 16132 Genoa, Italy; and §National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N228 MSC 1888, Bethesda, MD 20892 Edited by Anthony S. Fauci, National Institute of Allergy and Infectious Diseases, Bethesda, MD, and approved August 25, 1998 (received for review June 24, 1998) ABSTRACT The HIV-1 Tat protein is a potent chemoat- ceptors for some dual tropic HIV-1 strains (10, 11). A CCR2 tractant for monocytes. We observed that Tat shows conserved polymorphism has been found to correlate with delayed amino acids corresponding to critical sequences of the che- progression to AIDS (12, 13). mokines, a family of molecules known for their potent ability We report here that the HIV-1 Tat protein and the peptide to attract monocytes. Synthetic Tat and a peptide (CysL24–51) encompassing the cysteine-rich and core regions induce per- encompassing the ‘‘chemokine-like’’ region of Tat induced a tussis toxin sensitive Ca21 fluxes in monocytes.
    [Show full text]
  • Comprehensive Identification of Genes Driven by ERV9-Ltrs Reveals TNFRSF10B As a Re-Activatable Mediator of Testicular Cancer Cell Death
    Cell Death and Differentiation (2016) 23, 64–75 & 2016 Macmillan Publishers Limited All rights reserved 1350-9047/16 www.nature.com/cdd Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death U Beyer1,2,5, SK Krönung1,5, A Leha3, L Walter4 and M Dobbelstein*,1 The long terminal repeat (LTR) of human endogenous retrovirus type 9 (ERV9) acts as a germline-specific promoter that induces the expression of a proapoptotic isoform of the tumor suppressor homologue p63, GTAp63, in male germline cells. Testicular cancer cells silence this promoter, but inhibitors of histone deacetylases (HDACs) restore GTAp63 expression and give rise to apoptosis. We show here that numerous additional transcripts throughout the genome are driven by related ERV9-LTRs. 3' Rapid amplification of cDNA ends (3’RACE) was combined with next-generation sequencing to establish a large set of such mRNAs. HDAC inhibitors induce these ERV9-LTR-driven genes but not the LTRs from other ERVs. In particular, a transcript encoding the death receptor DR5 originates from an ERV9-LTR inserted upstream of the protein coding regions of the TNFRSF10B gene, and it shows an expression pattern similar to GTAp63. When treating testicular cancer cells with HDAC inhibitors as well as the death ligand TNF-related apoptosis-inducing ligand (TRAIL), rapid cell death was observed, which depended on TNFRSF10B expression. HDAC inhibitors also cooperate with cisplatin (cDDP) to promote apoptosis in testicular cancer cells. ERV9-LTRs not only drive a large set of human transcripts, but a subset of them acts in a proapoptotic manner.
    [Show full text]
  • Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3+ Regulatory T Cells
    Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3+ Regulatory T Cells This information is current as Hyung W. Lim, Jeeho Lee, Peter Hillsamer and Chang H. of September 28, 2021. Kim J Immunol 2008; 180:122-129; ; doi: 10.4049/jimmunol.180.1.122 http://www.jimmunol.org/content/180/1/122 Downloaded from References This article cites 44 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/180/1/122.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3؉ Regulatory T Cells1 Hyung W. Lim,* Jeeho Lee,* Peter Hillsamer,† and Chang H. Kim2* It is a question of interest whether Th17 cells express trafficking receptors unique to this Th cell lineage and migrate specifically to certain tissue sites.
    [Show full text]
  • Cytokine Modulators As Novel Therapies for Airway Disease
    Copyright #ERS Journals Ltd 2001 Eur Respir J 2001; 18: Suppl. 34, 67s–77s European Respiratory Journal DOI: 10.1183/09031936.01.00229901 ISSN 0904-1850 Printed in UK – all rights reserved ISBN 1-904097-20-0 Cytokine modulators as novel therapies for airway disease P.J. Barnes Cytokine modulators as novel therapies for airway disease. P.J. Barnes. #ERS Correspondence: P.J. Barnes Journals Ltd 2001. Dept of Thoracic Medicine ABSTRACT: Cytokines play a critical role in orchestrating and perpetuating National Heart & Lung Institute inflammation in asthma and chronic obstructive pulmonary disease (COPD), and Imperial College Dovehouse Street several specific cytokine and chemokine inhibitors are now in development for the future London SW3 6LY therapy of these diseases. UK Anti-interleukin (IL)-5 is very effective at reducing peripheral blood and airway Fax: 0207 3515675 eosinophil numbers, but does not appear to be effective against symptomatic asthma. Inhibition of IL-4 with soluble IL-4 receptors has shown promising early results in Keywords: Chemokine receptor asthma. Inhibitory cytokines, such as IL-10, interferons and IL-12 are less promising, cytokine as systemic delivery causes side-effects. Inhibition of tumour necrosis factor-a may be interleukin-4 useful in severe asthma and for treating severe COPD with systemic features. interleukin-5 interleukin-9 Many chemokines are involved in the inflammatory response of asthma and COPD interleukin-10 and several low-molecular-weight inhibitors of chemokine receptors are in development. CCR3 antagonists (which block eosinophil chemotaxis) and CXCR2 antagonists (which Received: March 26 2001 block neutrophil and monocyte chemotaxis) are in clinical development for the Accepted April 25 2001 treatment of asthma and COPD respectively.
    [Show full text]
  • Pathway-Selective Suppression of Chemokine Receptor Signaling in B Cells by LPS Through Downregulation of PLC-B2
    Cellular & Molecular Immunology (2010) 7, 428–439 ß 2010 CSI and USTC. All rights reserved 1672-7681/10 $32.00 www.nature.com/cmi RESEARCH ARTICLE Pathway-selective suppression of chemokine receptor signaling in B cells by LPS through downregulation of PLC-b2 Aiko-Konno Shirakawa1, Fang Liao1, Hongwei H Zhang1, Michael N Hedrick1, Satya P Singh1, Dianqing Wu2 and Joshua M Farber1 Lymphocyte activation leads to changes in chemokine receptor expression. There are limited data, however, on how lymphocyte activators can alter chemokine signaling by affecting downstream pathways. We hypothesized that B cell-activating agents might alter chemokine responses by affecting downstream signal transducers, and that such effects might differ depending on the activator. We found that activating mouse B cells using either anti-IgM or lipopolysaccharide (LPS) increased the surface expression of CCR6 and CCR7 with large increases in chemotaxis to their cognate ligands. By contrast, while anti-IgM also led to enhanced calcium responses, LPS-treated cells showed only small changes in calcium signaling as compared with cells that were freshly isolated. Of particular interest, we found that LPS caused a reduction in the level of B-cell phospholipase C (PLC)-b2 mRNA and protein. Data obtained using PLC-b22/2 mice showed that the b2 isoform mediates close to one-half the chemokine-induced calcium signal in resting and anti-IgM-activated B cells, and we found that calcium signals in the LPS-treated cells were boosted by increasing the level of PLC-b2 using transfection, consistent with a functional effect of downregulating PLC-b2. Together, our results show activator-specific effects on responses through B-cell chemokine receptors that are mediated by quantitative changes in a downstream signal-transducing protein, revealing an activity for LPS as a downregulator of PLC-b2, and a novel mechanism for controlling chemokine-induced signals in lymphocytes.
    [Show full text]
  • A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody
    Published OnlineFirst August 27, 2019; DOI: 10.1158/1078-0432.CCR-19-1090 Clinical Trials: Immunotherapy Clinical Cancer Research A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors Toshihiko Doi1, Kei Muro2, Hiroshi Ishii3, Terufumi Kato4, Takahiro Tsushima5, Mitsuhiro Takenoyama6, Satoshi Oizumi7, Kazuto Gemmoto8, Hideaki Suna8, Kouki Enokitani9, Tetsuyoshi Kawakami9, Hiroyoshi Nishikawa10,11, and Noboru Yamamoto12 Abstract Purpose: Regulatory T cells (Tregs) expressing CC chemo- part and 90 in the expansion part. No dose-limiting kine receptor 4 (CCR4) can suppress antitumor immune toxicities were observed in the dose-escalation part. Grade responses and are associated with poor prognoses in several 3/4 treatment-related adverse events (TRAEs) occurred in cancers. We assessed the safety and efficacy of combined 29% of patients in the expansion part (no grade 5 TRAEs). mogamulizumab (anti-CCR4 antibody) and nivolumab The most frequent TRAEs were rash (39%), rash maculopap- [anti-programmed death-1 (PD-1) antibody] in immunother- ular (20%), diarrhea (13%), stomatitis (12%), and pruritus apy-na€ve patients with advanced/metastatic solid tumors. (11%). There were four (27%) confirmed tumor responses Patients and Methods: This study (NCT02476123) com- among 15 patients with hepatocellular carcinoma, and prised dose-escalation (3þ3 design) and expansion parts. one confirmed and two unconfirmed responses among 15 Patients received nivolumab (3.0 mg/kg) every 2 weeks, with patients with pancreatic adenocarcinoma. During treatment, þ À mogamulizumab (0.3 or 1.0 mg/kg in dose escalation, populations of effector Tregs (CD4 CD45RA FoxP3high) þ 1.0 mg/kg in expansion) once weekly for 4 weeks, then every decreased and CD8 T cells in tumor-infiltrating lymphocytes 2 weeks, until progression or unacceptable toxicity.
    [Show full text]
  • Plasma Macrophage-Derived Chemokine (CCL22) and Its
    Egypt J Pediatr Allergy Immunol 2005; 3(1): 20-31. Original article Plasma macrophage-derived chemokine (CCL22) and its receptor CCR4 on peripheral blood T lymphocytes of asthmatic children Background: The macrophage-derived chemokine (MDC/CCL22) acts on Mohamed H. Ezzat, CC chemokine receptor-4 (CCR4) to direct trafficking and recruitment of T Karim Y. Shaheen*. helper-2 (TH2) cells into sites of allergic inflammation. It was previously found overexpressed in lesional samples from adult asthmatics. Objective: This study is aimed to investigate the participation of CCR4/MDC axis in the development of TH2-dominated allergen-induced From the Departments childhood asthma in relation to disease activity, attack severity, and of Pediatrics and response to therapy, and to outline its value in differentiating atopic asthma Clinical Pathology*, from infection-associated airway reactivity. Faculty of Medicine, Methods: Proportion of CCR4-expressing peripheral blood T lymphocytes Ain Shams University, + (CCR4 PBTL%) were purified and quantitated by negative selection from Cairo, Egypt. peripheral blood mononuclear cells by flow cytometry, and the concentration of MDC in plasma was measured by ELISA in 32 children with atopic asthma (during exacerbation and remission), as well as in 12 children with acute lower respiratory tract infections (ALRTI), and 20 healthy children serving as controls. Results: The mean plasma MDC level (925±471.5 pg/ml) and CCR4+PBTL% (55.3±23.6%) were significantly higher in asthmatic children during acute attacks in comparison to children with ALRTI (109±27.3 pg/ml and 27.6±7.5%) and healthy controls (99.6±25.6 pg/ml and 24.2±4.1%).
    [Show full text]
  • The Efficacy of Etanercept As Anti-Breast Cancer Treatment Is
    Shirmohammadi et al. BMC Cancer (2020) 20:836 https://doi.org/10.1186/s12885-020-07228-y RESEARCH ARTICLE Open Access The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages Elnaz Shirmohammadi1, Seyed-Esmaeil Sadat Ebrahimi1, Amir Farshchi2 and Mona Salimi3* Abstract Background: Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in breast cancer with conflicting results. Methods: Secretome data on MDA-MB-231 cancer cell-line were from public repositories and subjected to gene enrichment analyses. Since MDA-MB-231 cells secrete high levels of Granulocyte-Monocyte Colony Stimulating Factor, which activates macrophages to promote tumor growth, the effect of macrophage co-culturing on anticancer efficacy of Etanercept in breast cancer was evaluated using the Boolean network modeling and in vitro experiments including invasion, cell cycle, Annexin PI, and tetrazolium based viability assays and NFKB activity. Results: The secretome profile of MDA-MB-231 cells was similar to the expression of genes following treatment of breast cancer cells with TNF-α. Accordingly, inhibition of TNF-α by Etanercept decreased MDA-MB-231 cell survival, induced apoptosis and cell cycle arrest in vitro and inhibited NFKB activation. The inhibitory effect of Etanercept on cell viability, cell cycle progression, invasion and induction of apoptosis decreased following co-culturing of the cancer cells with macrophages. The Boolean network modeling of the changes in the dynamics of intracellular signaling pathways revealed NFKB activation by secretome of macrophages, leading to a decreased efficacy of Etanercept, suggesting NFKB inhibition as an alternative approach to inhibit cancer cell growth in the presence of macrophage crosstalk.
    [Show full text]
  • Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration
    Published OnlineFirst October 2, 2015; DOI: 10.1158/0008-5472.CAN-14-3499 Cancer Microenvironment and Immunology Research Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression David Anz1,2, Moritz Rapp1, Stephan Eiber1,2, Viktor H. Koelzer1, Raffael Thaler1, Sascha Haubner1, Max Knott1, Sarah Nagel1, Michaela Golic1, Gabriela M. Wiedemann1, Franz Bauernfeind3, Cornelia Wurzenberger1, Veit Hornung3,4, Christoph Scholz5, Doris Mayr6, Simon Rothenfusser1, Stefan Endres1, and Carole Bourquin1,7 Abstract The chemokine CCL22 is abundantly expressed in many tion. Mechanistic investigations indicated that Treg blockade types of cancer and is instrumental for intratumoral recruit- was a consequence of reduced intratumoral CCL22 levels ment of regulatory T cells (Treg), an important subset of caused by type I IFN. Notably, stable expression of CCL22 immunosuppressive and tumor-promoting lymphocytes. In abrogated the antitumor effects of treatment with RLR or this study, we offer evidence for a generalized strategy to TLR ligands. Taken together, our findings argue that type I blunt Treg activity that can limit immune escape and promote IFN blocks the Treg-attracting chemokine CCL22 and thus tumor rejection. Activation of innate immunity with Toll-like helps limit the recruitment of Treg to tumors, a finding with receptor (TLR) or RIG-I–like receptor (RLR) ligands prevented implications for cancer immunotherapy. Cancer Res; 75(21); 1– accumulation of Treg in tumors by blocking their immigra- 11. Ó2015 AACR. Introduction effector T-cell function ex vivo (1). Indeed, suppression of anti- cancer immunity is mediated predominantly by intratumoral Treg The chemokine CCL22 is abundantly expressed in the tissue of that suppress CD8 T-cell responses locally at the tumor site (6).
    [Show full text]